Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News CASI Pharmaceuticals Inc CASI

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its... see more

Recent & Breaking News (NDAQ:CASI)

CASI Pharmaceuticals Announces Poster Presentation At The 2020 AABB Virtual Annual Meeting

PR Newswire October 2, 2020

CASI Pharmaceuticals Announces Restructuring of Partnership with Juventas Cell Therapy Ltd

PR Newswire September 29, 2020

CASI Pharmaceuticals, Inc. to Participate in Two Upcoming September Conferences

PR Newswire September 11, 2020

CASI Pharmaceuticals Announces Second Quarter 2020 Financial Results

PR Newswire August 10, 2020

CASI Pharmaceuticals To Report Second Quarter 2020 Financial Results And Host Conference Call August 10, 2020

PR Newswire August 3, 2020

CASI Pharmaceuticals Announces Pricing Of $38,000,000 Public Offering Of Common Stock

PR Newswire July 22, 2020

CASI Pharmaceuticals Announces Proposed Public Offering Of Common Stock

PR Newswire July 21, 2020

CASI Pharmaceuticals Announces Submission Of Clinical Trial Application (IND) To Conduct Phase 1 Study For Anti-38 Monoclonal Antibody Program

PR Newswire June 8, 2020

CASI Pharmaceuticals To Present At The Jefferies 2020 Healthcare Conference

PR Newswire June 2, 2020

CASI Pharmaceuticals Announces First Quarter 2020 Financial Results

PR Newswire May 11, 2020

CASI Pharmaceuticals To Present at 2020 Solebury Trout Virtual Investor Conference

PR Newswire April 7, 2020

CASI Pharmaceuticals Announces Full Year 2019 Financial Results

PR Newswire March 16, 2020

CASI Pharmaceuticals Announces China NMPA Approval Of CNCT19 (CD19 CAR-T) Clinical Trial Applications

PR Newswire December 3, 2019

CASI Pharmaceuticals Announces Third Quarter 2019 Financial Results

PR Newswire November 12, 2019

CASI Pharmaceuticals Enters Exclusive China Distribution License Agreement For Octreotide Long Acting Injectable (LAI) Microsphere For Neuroendocrine Cancers And Acromegaly

PR Newswire November 7, 2019

CASI Pharmaceuticals Announces The Promotion Of Larry Zhang To President

PR Newswire September 19, 2019

China NMPA Accepts Clinical Trial Application For CASI's CD19 CAR-T-Product

PR Newswire September 16, 2019

CASI Pharmaceuticals, Inc. to Host Key Opinion Leader Symposium on September 10, 2019 in New York City

PR Newswire September 5, 2019

CASI Pharmaceuticals, Inc. To Present At The 2019 H.C. Wainwright 21st Annual Global Investment Conference

PR Newswire September 3, 2019

CASI Pharmaceuticals Announces Launch of EVOMELA® (melphalan for injection) in China

PR Newswire August 12, 2019